VERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA
BOSTON, MA
Loading...
Price History
Market Data
| Market Cap | 141.37B |
| P/E Ratio | - |
| P/B Ratio | 7.57 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 0.37 |
| Current Ratio | 2.90 |
| Currency | USD |
Key Financial Metrics
12.00B
Revenue
3.95B
Net Income
-
EPS (Diluted)
5.68B
Free Cash Flow
Profitability
Gross Margin
86.2%
Operating Margin
34.8%
Net Profit Margin
32.9%
EBITDA
4.43B
Returns & Efficiency
Return on Assets (ROA)
15.4%
Return on Equity (ROE)
21.2%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
25.64B
Total Debt
-
Debt to Equity
0.37x
Current Ratio
2.90
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| HQ | BOSTON, MA |
| Fiscal Year | 2025 |
Peers
LILLY ELI & CO
LLY
954.09B
P/E: --
ELI LILLY & CO
LLY
954.09B
P/E: --
530.38B
P/E: --
ABBVIE INC.
ABBV
387.52B
P/E: --
270.21B
P/E: --
MERCK & CO. INC.
MRK
270.21B
P/E: --
270.21B
P/E: --
186.96B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$141.37B
P/E Ratio (TTM)-
Price to Book7.57
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin86.2%
Operating Margin34.8%
Net Margin32.9%
ROE21.2%
ROA15.4%
Leverage & Liquidity
Debt to Equity0.37
Current Ratio2.90
Total Debt-
Total Assets$25.64B
Stockholders' Equity$18.67B
Income Statement (FY 2025)
Revenue$12.00B
Gross Profit$10.35B
Operating Income$4.17B
Net Income$3.95B
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$5.68B
Cash & Equivalents$5.08B
Revenue Growth8.9%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 50 NORTHERN AVENUE BOSTON, MA 02210 |
| Phone | 6173416393 |
| Incorporated | MA, US |
| EIN | 043039129 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 254.03M |
| Stockholders' Equity | $18.67B |
| Cash & Equivalents | $5.08B |
Recent Filings
View All
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-05-06
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-05-05
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2026-05-05
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-05-04
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-05-04
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-04-30
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | VERTEX PHARMACEUTICALS INC / MA |
| Ticker | VRTX |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | -- |
| Headquarters | BOSTON, MA |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 141.37B |
| Revenue | 12.00B |
| Net Income | 3.95B |
| P/E Ratio | - |
| EPS | - |
| Net Margin | 32.9% |
| ROE | 21.2% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...